There are currently 196 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.
Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients
NCT04634435
Recruiting
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of cytokine induced memory-like (CIML) NK cells plus KP1237 and low dose IL-2 in newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
08/28/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
NCT05908396
Recruiting
This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participants with relapsed and/or refractory MM, for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate. Dose escalation and dose expansion cohorts will be enrolled to evaluate safety, preliminary efficacy, and further define a RP2D. The total length of the study, from screening of the first parti... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: City of Hope, Duarte, California +4 locations
Conditions: Multiple Myeloma
Register for Updates
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2023
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +727 locations
Conditions: Multiple Myeloma
Register for Updates
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
NCT05706766
Recruiting
The goal of this research study is to investigate whether a virtual, home-based, prehabilitation aerobic and resistance exercise (PARE) training program implemented 8 weeks prior to receiving autologous stem cell transplant (ASCT) for multiple myeloma participants will improve muscular strength, physical capacity, patient reported outcomes, and cardiometabolic health outcomes. The names of the study interventions involved in this study are: Prehabilitative aerobic and resistance exercise (PARE... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/10/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Multiple Myeloma, Stem Cell Transplant Complications
Register for Updates
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
NCT05974150
Recruiting
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/08/2023
Locations: Yale Cancer Center, New Haven, Connecticut +6 locations
Conditions: Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Acute Myelogenous Leukemia
Register for Updates
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
NCT05469893
Recruiting
The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressing to active multiple myeloma (MM). Multiple Myeloma is a cancer of the plasma cells, which are an important part of the immune system. Patients with active multiple myeloma generally require treatmen... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/30/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
Register for Updates
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
NCT03689595
Recruiting
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Gender:
All
Ages:
30 years and above
Trial Updated:
07/30/2023
Locations: The Johns Hopkins Hospital, Baltimore, Maryland +2 locations
Conditions: Multiple Myeloma
Register for Updates
Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
NCT04635189
Recruiting
The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
07/17/2023
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Multiple Myeloma
Register for Updates
Umbilical Cord Blood Transplantation From Unrelated Donors
NCT03016806
Recruiting
This study is a single-center, treatment protocol with 4 possible preparative regimens, designed to validate the process of umbilical cord blood stem cell transplantation at our institution.
Gender:
All
Ages:
Between 2 months and 75 years
Trial Updated:
07/17/2023
Locations: Wilmot Cancer Institute, Rochester, New York
Conditions: Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder, Aplastic Anemia, Myelodysplastic Syndromes, Chronic Leukemia, Lymphoma, Multiple Myeloma, Solid Tumor
Register for Updates
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
NCT04731844
Recruiting
To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/13/2023
Locations: University of Rochester, Rochester, New York
Conditions: Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM), Monoclonal Gammopathy of Undetermined Significance
Register for Updates
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043
Recruiting
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/13/2023
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia +15 locations
Conditions: Multiple Myeloma, Plasma Cell Disorder
Register for Updates
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05431608
Recruiting
A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/13/2023
Locations: Memorial Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey +6 locations
Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
Register for Updates